Page 33 - SOGIBA 1 2020

Estudio molecular para brca1 y brca2 en síndrome de cáncer de mama y ovario hereditario...

13. Friebel TM et al. Bilateral prophylactic oopho- 20. Armstrong DK. Relapsed ovarian cancer: cha-
rectomy and bilateral prophylactic mastectomy llenges and management strategies for a chronic
in a prospective cohort of unaffected BRCA1 and disease. Oncologist. 2002;7 (Suppl 5):20–28.
BRCA2 mutation carriers. Clin Breast Cancer. 21. Swart A. Long-term follow-up of women enrolled
2007;7(11):875–882. in a randomized trial of adjuvant chemotherapy
14. Manchanda R et al. Factors influencing uptake for early stage ovarian cancer. In: ASCO Annual
and timing of risk-reducing salpingooophorec- Meeting Proceedings (Part I). 2007: Abstract 25,
tomy in women at risk of familial ovarian cancer: p. 18S (June 20 Supplement): 5509. J Clin Oncol.
acompeting risk time to event analysis. BJOG. 22. Lyratzopoulos G et al. Variation in advanced sta-
2012;119(5):527–536. ge at diagnosis of lung and female breast cancer
15. Nelson HD et al. Risk Assessment, Genetic Coun- in an English region 2006–2009. Br J Cancer.
seling, and Genetic Testing for BRCA-Related 2012;106(6):1068–1075.
Cancer: Systematic Review to Update the U.S. 23. NICE. National costing report: Early and locally
Preventive Services Task Force Recommendation. advanced breast cancer/Advanced breast cancer.
Agency for Healthcare Research and Quality (US); In: London, UK: National Institute for Health and
2013. Clinical Excellence; 2009.
16. Finch A et al. Salpingo-oophorectomy and the risk 24. Gennari A et al. Survival of metastatic breast
of ovarian, fallopian tube, and peritoneal cancers carcinoma patients over a 20-year period: a
in women with a BRCA1 or BRCA2 Mutation. retrospective analysis based on individual pa-
JAMA.2006;296(2):185–192. tient data from six consecutive studies. Cancer.
17. Rebbeck TR et al. Meta-analysis of risk reduction 2005;104(8):1742–1750.
estimates associated with risk-reducing salpin- 25. Manchanda R et al. Cost-effectiveness of popula-
gooophorectomy in BRCA1 or BRCA2 mutation tion screening for BRCA mutations in Ashkenazi
carriers. J Natl Cancer Inst. 2009;101(2):80–87. jewish women compared with family history-
18. Rebbeck TR et al. Bilateral prophylactic mastec- based testing. J Natl Cancer Inst. 2014 Nov
tomy reduces breast cancer risk in BRCA1 and 30;107(1):380.
BRCA2 mutation carriers: the PROSE Study 26. Kwon JS et al. Preventing future cancers by testing
Group. J Clin Oncol. 2004;22(6):1055–1062. women with ovarian cancer for BRCA mutations.
J Clin Oncol. 2010 Feb 1;28(4):675-82.
19. Yancik R. Ovarian cancer. Age contrasts in inci-
dence, histology, disease stage at diagnosis, and
mortality. Cancer. 1993;71(2 Suppl):517–523.

Volumen 99 - Nº 1007 - Agosto 2020 31